ABEO

Abeona Therapeutics Inc

Add to Watchlist

Advanced Chart

6.800

+0.05(0.741%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.935

Open

6.770

VWAP

6.81

Vol

482.31K

Mkt Cap

347.87M

Low

6.730

Amount

3.28M

EV/EBITDA(TTM)

Total Shares

40.96M

283.00M

EV/OCF(TTM)

P/S(TTM)

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).

5 Analyst Rating

210.29% Upside

Wall Street analysts forecast ABEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABEO is 21.10 USD with a low forecast of 19.00 USD and a high forecast of 27.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

210.29% Upside

Current: 6.800

Low

19.00

Averages

21.10

High

27.50

210.29% Upside

Current: 6.800

Low

19.00

Averages

21.10

High

27.50

Oppenheimer

Outperform

initiated

$19

2025-06-02

Reason

Oppenheimer

Price Target

$19

2025-06-02

initiated

Outperform

Reason

Oppenheimer assumed coverage of Abeona Therapeutics with an Outperform rating and $19 price target. The firm notes Abeona's Q1 update highlighted strong early momentum following ZEVASKYN's April approval. The first Qualified Treatment Center has been activated ahead of schedule with the first patient on track for treatment in Q3 2025. Enthusiasm from patients/caregivers and physicians remains high. Notably, management highlighted strong interest at the SID conference, Oppenheimer adds. Based on the early launch progress, the firm's confidence in ZEVASKYN's commercial trajectory is reaffirmed.

Stifel

Stephen Willey

Buy

downgrade

$21 -> $20

2025-05-16

Reason

Stifel

Stephen Willey

Price Target

$21 -> $20

2025-05-16

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Abeona Therapeutics to $20 from $21 and keeps a Buy rating on the shares. The firm views the recent activation of the first Zevaskyn Qualified Treatment Center and the anticipated treatment of the first patient in August 2025 as "an encouraging development," the analyst tells investors in a Q1 recap note.

Alliance Global Partners

analyst

Buy

maintain

$25

2025-05-15

Reason

Alliance Global Partners

analyst

Price Target

$25

2025-05-15

maintain

Buy

Reason

Alliance Global Partners raised the firm's price target on Abeona Therapeutics to $27.50 from $25 and keeps a Buy rating on the shares. Abeona announced Q1 results following the recent news of their FDA approval for Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa, notes the analyst, who also points out that the company recently entered into an agreement to sell the Rare Pediatric Disease Priority Review Voucher it was granted for $155M, allowing for additional funding. The firm values Zevaskyn for RDEB at $24 per share and the remaining pipeline, which includes ABO-102 for Sanfilippo syndrome and three preclinical programs, and cash at $3.50 per share.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$15

2025-03-24

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$15

2025-03-24

Reiterates

Strong Buy

Reason

Oppenheimer

Francois Brisebois

Buy

Initiates

$16

2025-03-05

Reason

Oppenheimer

Francois Brisebois

Price Target

$16

2025-03-05

Initiates

Buy

Reason

Oppenheimer initiated coverage of Abeona Therapeutics with an Outperform rating and $16 price target. The company's main value driver is pz-cel, or genetically engineered autologous skin sheets, for the treatment of recessive dystrophic epidermolysis bullosa, the analyst tells investors in a research note. The firm is optimistic about pz-cel's complete response letter resolution and approval into the April 29 FDA action date. With a likely imminent CRL resolution, Abeona is "particularly attractive at these levels," contends Oppenheimer.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$15

2025-02-19

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$15

2025-02-19

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Abeona Therapeutics Inc (ABEO.O) is 238.52, compared to its 5-year average forward P/E of 3.03. For a more detailed relative valuation and DCF analysis to assess Abeona Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

3.03

Current PE

238.52

Overvalued PE

39.88

Undervalued PE

-33.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

179.48

Current PS

4.73

Overvalued PS

431.87

Undervalued PS

-72.91

Financials

Annual

Quarterly

FY2025Q1

0.00

Total Revenue

FY2025Q1

YoY :

+37.66%

-19.73M

Operating Profit

FY2025Q1

YoY :

-61.91%

-12.03M

Net Income after Tax

FY2025Q1

YoY :

-79.31%

-0.24

EPS - Diluted

FY2025Q1

YoY :

+29.75%

-19.80M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

YoY :

-100.00%

N/A

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.5M

USD

3-6

Months

119.5K

USD

6-9

Months

41.9K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

1.5M

USD

3-6

Months

119.5K

USD

6-9

Months

41.9K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABEO News & Events

Events Timeline

2025-07-29 (ET)

2025-07-29

10:36:17

AscellaHealth highlights value of HUB partnership with Abeona Therapeutics

2025-07-15 (ET)

2025-07-15

07:38:06

Abeona announces ZEVASKYN available at new Qualified Treatment Center

2025-07-02 (ET)

2025-07-02

07:33:27

Abeona Therapeutics closes sale of Rare Pediatric Disease PRV for $155M

News

7.5

07-29Newsfilter

AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients

5.0

07-15Newsfilter

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

4.0

07-14Benzinga

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target